Clinical trial Recruiting at 1 site Phase 4 Interventional Ages Any age to 72 Hours

Optimizing hydrocortisone therapy for newborns undergoing hypothermia treatment after asphyxia

Official title: Hydrocortisone Therapy Optimization During Hypothermia Treatment in Asphyxiated Neonates - a Pharmacokinetic Study

Run by Semmelweis University · NCT05836610 · Data updated 2026-11-12

This study is testing how to best use hydrocortisone treatment for newborns who have had trouble breathing at birth and are being cooled to help their recovery.

Quick facts

PhasePhase 4
Study typeInterventional
AgesAny age to 72 Hours
SexAll
Enrollment50 (estimated)
SponsorSemmelweis University
Academic / other
Locations1 site (Budapest, Pest County)
StatusRecruiting
StartedSeptember 21, 2021
Main results expectedSeptember 2027
Study endsSeptember 2027
Registry record updatedApril 28, 2026
Trial IDNCT05836610 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are newborns with a gestational age of 36 weeks or more who are undergoing whole-body hypothermia treatment due to systemic hypotension.

Probably not a fit

Patients who are older than 6 hours at the time of treatment or have critical congenital abnormalities or genetic diseases may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the pharmacokinetics of intravenous hydrocortisone therapy in asphyxiated newborns receiving therapeutic hypothermia. The study aims to personalize steroid supplementation by measuring serum cortisol levels before and after hydrocortisone administration. By understanding how hypothermia affects drug metabolism, the researchers hope to determine the optimal dosing of hydrocortisone to improve hemodynamic stability in these vulnerable infants. The ultimate goal is to enhance the safety and effectiveness of care for newborns suffering from birth asphyxia and low blood pressure.

Why it matters

Potential benefit: If successful, this study could lead to more personalized and effective treatment protocols for asphyxiated neonates, potentially improving their survival and long-term outcomes.

How similar studies have gone: Previous studies have shown that low-dose hydrocortisone can be effective in treating cardiovascular impairment in asphyxiated neonates, indicating potential for success in this novel approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* gestational age ≥ 36 weeks
* provision of whole-body hypothermia treatment (as described by Azzopardi et al.)
* presence of systemic hypotension (defined as a mean arterial pressure less than the gestational age in weeks)
* indication for hydrocortisone treatment during hypothermia by the attending physician
* indwelling arterial catheter to take blood samples without additional painful punctures: umbilical arterial catheter or peripheral arterial catheter
* written informed parental consent

Exclusion Criteria:

* infants who are expected to be \> 6 hours of age (not suitable for cooling)
* critical congenital abnormalities
* genetic disease
* signed informed consent is unavailable

Where it's running

  • Semmelweis University Department of Pediatrics (Bókay street Unit)
    Budapest, Pest County, Hungary
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.